Tow lines has been broken!!!!!!!!!We may see a breakthrough to 7$, NASDAQ:IBRX , FDA Approves ImmunityBio's Bladder Cancer Drug.
−1.13USD
−583.20 MUSD
622.00 KUSD
136.93 M
About ImmunityBio, Inc.
Sector
CEO
Richard Adcock
Headquarters
San Diego
Website
Employees (FY)
628
Founded
2014
FIGI
BBG007T9DYW9
ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.
ibrx might ne a 8 dollar stock maybe ill put in a pic later, but with the look of it it seems like a 8 dollar stock
$IBRX A Step Towards Better ImmunotherapyWhile most oncological treatments focus on bombarding the body with toxic materials in hopes of killing cancerous cells, ImmunityBio, Inc. (Nasdaq: IBRX) utilizes immunology in order to find a solution. Its treatments usually focus on catalyzing NK cells, and T cells, which then kill cancerous cells
IBRX - PDUFA - short squeezeThis is not a financial advice!
Upcoming catalyst and block buys recently.
SL under 1.6
Key level: 2.0 must be broken and hold for bullish confirmation.
TP around 5.0
Only 83.44M float
32% Short float
Most info on the chart.
Trade carefully!
IBRX- LongBreaking prior resistance.
Has support at the 10 EMA and 50 MA.
Higher highs, higher lows.
82 Million float
Descending triangle on $ibrxDescending triangle, RSI about to cross / has crossed into 50s, OBV is printing a bullish flag, it broke 50/20 emas.
We may be looking at a break to high 5s / low 6.
$IBRX - If $11.23 breaks, $8.78 possibleHas been unable to find bottom yet.
There is a chance of consolidating or reversal from around $11.23 area due to oversold condition.
If there is further break down, the next support area is $8.78, which could be a strong support.
Good case - consolidate or reversal from $11.23
Best case - $12.70
12.5 or 16 - will Hit 21 ZONECASE1 : If tomorrow if it follows up trend ( 16) - could hit 20 to 21 Zone
CASE :If tomorrow Down trend - Will fall below 13 and will hit 12.5 - Will bounce back and will reach 16-21 zone this week
IBRX updateAfter breaking its potential upward moving channel, it bounced back from a support line. As of now, it is around a resistance. If it can pass and hold tomorrow, it may visit some higher values, as $19.40. If it cannot hold, then it will probably drop to about $17.2.
IBRX may go higherIBRX has broken its downward trend and trying to move up. If it can break through the resistance, it will start forming an upward moving channel.
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of IBRX is 4.82 USD — it has decreased by 12.20% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange ImmunityBio, Inc. stocks are traded under the ticker IBRX.
ImmunityBio, Inc. is going to release the next earnings report on May 7, 2024. Keep track of upcoming events with our Earnings Calendar.
IBRX stock is 19.42% volatile and has beta coefficient of 1.25. Check out the list of the most volatile stocks — is ImmunityBio, Inc. there?
IBRX earnings for the last quarter are −0.19 USD per share, whereas the estimation was −0.26 USD resulting in a 25.49% surprise. The estimated earnings for the next quarter are −0.18 USD per share. See more details about ImmunityBio, Inc. earnings.
Yes, you can track ImmunityBio, Inc. financials in yearly and quarterly reports right on TradingView.
IBRX stock has fallen by 5.30% compared to the previous week, the month change is a 21.50% fall, over the last year ImmunityBio, Inc. has showed a 97.54% increase.
IBRX net income for the last quarter is −233.39 M USD, while the quarter before that showed −95.58 M USD of net income which accounts for −144.18% change. Track more ImmunityBio, Inc. financial stats to get the full picture.
Today ImmunityBio, Inc. has the market capitalization of 3.70 B, it has increased by 0.41% over the last week.
No, IBRX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, IBRX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ImmunityBio, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 25, 2024, the company has 628.00 employees. See our rating of the largest employees — is ImmunityBio, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ImmunityBio, Inc. technincal analysis shows the sell today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ImmunityBio, Inc. stock shows the neutral signal. See more of ImmunityBio, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on ImmunityBio, Inc. future price: according to them, IBRX price has a max estimate of 5.00 USD and a min estimate of 5.00 USD. Read a more detailed ImmunityBio, Inc. forecast: see what analysts think of ImmunityBio, Inc. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ImmunityBio, Inc. EBITDA is −339.62 M USD, and current EBITDA margin is −55.12 K%. See more stats in ImmunityBio, Inc. financial statements.